Date of submission of the HTAC Recommendation: 27 March 2026Date of notification to HTAC on the SOH decision: 18 June 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on pneumococcal vaccines for the prevention of diseases caused by Streptococcus pneumoniae in elderly adults 60 years old and above, continue reading : HTA Council Final Recommendation on Pneumococcal Vaccines for the Prevention of Diseases caused by Streptococcus pneumoniae in Adults 60 years old and above (with Secretary of Health Decision)
HTA Council Final Recommendation on Multiple Micronutrient Supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and reduction of anemia among pregnant and lactating women (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 13 February 2026Date of notification to HTAC on the SOH decision: 02 June 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on multiple micronutrient supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and continue reading : HTA Council Final Recommendation on Multiple Micronutrient Supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and reduction of anemia among pregnant and lactating women (with Secretary of Health Decision)
HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 18 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) Mutation Test for the diagnosis of EGFR mutations in patients continue reading : HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
HTA Council Final Recommendation on erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), gefitinib (250 mg tablet and film-coated tablet), and afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation – postitive Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 12 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), Gefitinib (250 mg tablet and film-coated tablet), and Afatinib continue reading : HTA Council Final Recommendation on erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), gefitinib (250 mg tablet and film-coated tablet), and afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation – postitive Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
HTA Council Final Recommendation on Atezolizumab [60 mg/mL, 20 mL vial for Intravenous (IV) Infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for Intravenous (IV) Infusion] and Lenvatinib [4 mg or 10 mg capsule] for adults diagnosed with advanced or unresectable Hepatocellular Carcinoma (uHCC) (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 19 January 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 continue reading : HTA Council Final Recommendation on Atezolizumab [60 mg/mL, 20 mL vial for Intravenous (IV) Infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for Intravenous (IV) Infusion] and Lenvatinib [4 mg or 10 mg capsule] for adults diagnosed with advanced or unresectable Hepatocellular Carcinoma (uHCC) (with Secretary of Health Decision)